PNC-27
PNC-27 (p53 HDM-2-binding domain peptide)
Overview
PNC-27 is a synthetic peptide designed to selectively kill cancer cells by targeting HDM-2 — a protein overexpressed on the membranes of cancer cells but not normal cells. PNC-27 incorporates a sequence from the p53 tumor suppressor that binds HDM-2 combined with a membrane-penetrating leader sequence. In preclinical research PNC-27 has demonstrated selective cytotoxicity against multiple cancer cell lines including breast pancreatic and leukemia cells without affecting normal cells. It represents an innovative approach to cancer peptide therapeutics exploiting a surface marker specific to malignant cells.
Mechanism of Action
HDM-2 (the human ortholog of MDM-2) is normally an intracellular protein that regulates p53 activity but is aberrantly expressed on the outer plasma membrane of cancer cells — a phenomenon not observed in normal healthy cells. PNC-27 is designed to bind specifically to this membrane-expressed HDM-2 creating pores in the cancer cell membrane that lead to cell lysis. The leader sequence PLFGRKP facilitates membrane insertion while the p53-derived sequence provides HDM-2 binding specificity. This mechanism differs fundamentally from conventional chemotherapy — it does not target DNA or rapidly dividing cells generally but specifically exploits the cancer-specific membrane expression of HDM-2. In cell culture studies PNC-27 induced rapid necrosis of cancer cells within hours with no toxicity to normal cells at the same concentrations.
Where does PNC-27 sit?
See how this peptide compares across all 85 peptides in our database.
Dosage Information
Typical Dose
Research compound — no established human dosing
Frequency
N/A
Administration
Intravenous in research settings
Notes
Primarily a research compound. No completed human clinical trials. Several in vitro and animal studies showing selective cancer cell killing. Not a substitute for established cancer treatments.
Compound Data
Molecular Formula
C14H17N3O6
Molecular Weight
323.30 g/mol
IUPAC Name
2-[[5-[(4-nitrophenyl)methylamino]-5-oxopentanoyl]amino]acetic acid
PubChem CID
449243Potential Side Effects
Community Experiences
No experiences shared yet. Be the first!
Quick Facts
- Administration
- Intravenous in research settings
- Typical Dose
- Research compound — no established human dosing
- Frequency
- N/A
- References
- 0 curated + 4 from PubMed
- Evidence Score
- 13.2 / 100